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(DIPGs), a pediatric glioma with 2-year survival rate of less than 10%. 
ACVR1mutations frequently coincide with activating PIK3CA or PIK3R1 
mutations, indicating a potential cooperative effect of BMP and PI3K 
signaling in gliomagenesis. We used genetically engineered mice with indu-
cible knock-in of Acvr1R206H or Pik3caE545K alleles, such that cre-mediated 
recombination resulted in expression of the gain of function mutated genes 
from their endogenous promoters at physiological levels. Cre-mediated 
deletion in GFAP-CreER;Pik3caE545K/+;p53cKO mice (Pik3ca;p53) me-
diated Trp53 deletion and expression of Pik3caE545K in glial progen-
itors, and spontaneously induced high-grade glioma (HGG) in mice with 
complete penetrance. Heterozygous knock-in of the Acvr1R206H al-
lele accelerated tumorigenesis and impaired survival in Pik3ca;p53 mice 
(Acvr1;Pik3ca;p53). Transcriptomic analysis of Acvr1;Pik3ca;p53 tumors 
compared to Pik3ca;p53 littermate controls, as in patient-derived tumors, 
revealed broad molecular signatures associated with cell fate commitment 
and chromosome maintenance. Pharmacologic inhibition of ACVR1 was 
sufficient to impair growth in human patient-derived DIPG cell lines. To-
gether, our studies show that ACVR1 activation promotes tumor growth in 
spontaneous mouse HGG and patient-derived DIPG cells, suggesting that 
ACVR1 inhibition may produce a clinically significant therapeutic effect in 
DIPG.
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Sharon Gardner1, Rohinton Tarapore2, Jeffrey Allen1, Wafik Zaky3, 
Yazmin Odia4, Matthew Hall4, Doured Daghistani4, Ziad Khatib5, 
Carl Koschmann6, Dolly Aguilera7, Tobey MacDonald7, Maryam Fouladi8, 
Susan McGovern3, Cassie Kline9, Nicholas Vitanza10, Guangrong Lu2, 
Krystal Merdinger2, Wolfgang Oster2, Joshua Allen2, and Soumen Khatua3; 
1NYU Langone Medical Center and School of Medicine, New York, NY, 
USA, 2Oncoceutics, Inc, Philadelphia, PA, USA, 3The University of Texas 
MD Anderson Cancer Center, Houston, TX, USA, 4Miami Cancer Institute, 
Baptist Health South Florida, Miami, FL, USA, 5Nicklaus Children’s 
Hospital, Miami, FL, USA, 6Michigan Medicine, University of Michigan 
Medical School, Ann Arbor, MI, USA, 7Children’s Healthcare of Atlanta, 
Emory University School of Medicine, Atlanta, GA, USA, 8Cincinnati 
Children’s Hospital, Cincinnati, OH, USA, 9University of California San 
Francisco, San Francisco, CA, USA, 10Seattle Children’s Hospital, Seattle, 
WA, USA
H3 K27M-mutant gliomas often manifest as midline gliomas, have a 
dismal prognosis, and have no effective treatments. ONC201 efficacy 
has been shown in high-grade glioma preclinical models and durable re-
sponses with single agent ONC201 have been reported in adults with 
recurrent H3 K27M-mutant gliomas. These observations led to a Phase 
I  pediatric clinical trial of ONC201 dosed by body weight. This multi-
center, open-label, 3 + 3 dose-escalation and dose-expansion clinical trial 
(NCT03416530) for H3 K27M-mutant glioma or non-biopsied DIPG has 
6 arms: arms A  and E determine the RP2D in pediatric post-radiation 
(recurrent or not-recurrent) H3 K27M-mutant glioma patients with 
ONC201 administered as an oral capsule as well as a liquid formulation, 
respectively. Both arms have completed accrual. The study is currently 
enrolling newly diagnosed DIPG patients to determine the RP2D for 
ONC201 in combination with radiation (arm B). Dedicated assessment 
of intratumoral ONC201 concentrations in midline gliomas patients (arm 
C) and the effects of ONC201 in H3K27M DNA levels in circulating 
CSF (arm D) are currently enrolling patients. ONC201 as a single agent 
in patients with progressive H3K27M mutant tumors following irradi-
ation (excluding DIPG/spinal cord tumors) was recently opened (arm F). 
Once the RP2D is confirmed, there is a dose-expansion cohort to confirm 
the safety, radiographic efficacy and survival with ONC201. The primary 
endpoints of arms A, B, and E have been established with the RP2D of 
625mg scaled by body weight as a capsule or liquid formulation admin-
istered alone or in combination with radiation without incidence of dose-
limiting toxicity.
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INTRODUCTION: We have previously found that up to 15% of all 
DIPGs harbor mutations in PPM1D, resulting in the expression of an acti-
vated and truncated PPM1D (PPM1Dtr). Here we evaluate the mechanisms 
through which PPM1Dtr enhances glioma formation and identify its asso-
ciated therapeutic vulnerabilities. METHODS: We have developed multiple 
in vitro and in vivo models of PPM1D-mutant DIPGs and applied quanti-
tative proteomic and functional genomic approaches to identify pathways 
altered by PPM1Dtr and associated dependencies.  RESULTS: PPM1D 
mutations are clonal events that are anti-correlated to TP53 mutations. We 
find ectopic expression of PPM1Dtr to be sufficient to enhance glioma for-
mation and to be necessary in PPM1D-mutant DIPG cells. In addition, en-
dogenous truncation of PPM1D is sufficient to enhance glioma formation 
in the presence of mutant H3F3A and PDGFRA. PPM1Dtr overexpression 
attenuates g-H2AX formation and suppresses apoptosis and cell-cycle ar-
rest in response to radiation treatment. Deep scale phosphoproteomics ana-
lyses reveal DNA-damage and cell cycle pathways to be most significantly 
associated with PPM1Dtr. Furthermore, preliminary analysis of genome-
wide loss-of-function CRISPR/Cas9 screens in isogenic GFP and PPM1Dtr 
overexpressing mouse neural stem cells reveal differential dependency on 
DNA-damage response genes in the PPM1Dtr overexpressing cells. Con-
sistent with PPM1D’s role in stabilizing MDM2, PPM1D-mutant DIPG 
models are sensitive to a panel of MDM2 inhibitors (Nutlin-3a, RG7388, 
and AMG232). CONCLUSION: Our study shows that PPM1Dtr is both 
an oncogene and a dependency in PPM1D- mutant DIPG, and there are 
novel therapeutic vulnerabilities associated with PPM1D that may be ex-
ploited.
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Diffuse intrinsic pontine gliomas (DIPG) are the most common brain-
stem tumors of childhood and represent one of the most challenging paedi-
atric tumours to treat. A non-randomized, open label phase II pilot study 
was conducted at Fondazione IRCCS Istituto Nazionale Tumori (Milan) 
to assess the efficacy in terms of objective response rate according to the 
RECIST criteria of combining nimotuzumab and vinorelbine with radi-
ation in newly-diagnosed DIPG. Serum specimens were collected at baseline. 
microRNA expression profiling was performed using Agilent platform and 
Human miRNA SureSelect 8x60K containing 2006 miRNAs annotated on 
miRBase19.0. Primary data analysis yielded a matrix containing 330 de-
tectable miRNA. Association with PFS allowed us to disclose a signature of 
10 miRNAs able to stratify high and low risk patients (HR=4.33, 95%CI 
1.49–12.54; p=4.27E-05). To test the 10 ct-miRNA model performance, 
we collected an independent cohort of the same sample size (n=24) and we 
derived the index values and risk stratification. The distribution of index 
values covers a range similar to the discovery cohort. Imposing the signature 
threshold patients were divided in high/low risk and Kaplan-Meier curves 
confirmed the different PFS time for the two groups with HR=3.5 (95%CI: 
1.8–8.01, p-value=0.0002) for the high-risk patients, reaching AUC=0.833. 
Our signature is a biomarker based on non-invasive procedures for prog-
nosis able to enter into clinical practice. Further validation on multicenter 
case series is warranted.
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